Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Medicina (B.Aires) ; 79(4): 295-298, ago. 2019. ilus
Article in Spanish | LILACS | ID: biblio-1040526

ABSTRACT

Se denomina mieloptisis a la infiltración de la médula ósea por células no hematopoyéticas. En pacientes con cáncer gástrico esta invasión es extremadamente infrecuente y la supervivencia suele ser menor a tres meses. Presentamos el caso de un hombre de 35 años con compromiso de la médula ósea secundario a un carcinoma gástrico difuso de células en anillo de sello.


The infiltration of the bone marrow y non-hematopoietic cells is called myelophthisis. In patients with gastric cancer, this invasion is extremely infrequent and the survival is usually less than three months. We present the case of a 35-year-old man with bone marrow involvement secondary to diffuse gastric carcinoma of signet ring cells.


Subject(s)
Humans , Male , Adult , Stomach Neoplasms/diagnosis , Carcinoma, Signet Ring Cell/diagnosis , Anemia, Myelophthisic/diagnosis , Stomach Neoplasms/complications , Stomach Neoplasms/drug therapy , Fatal Outcome , Carcinoma, Signet Ring Cell/complications , Carcinoma, Signet Ring Cell/drug therapy , Anemia, Myelophthisic/etiology
3.
Indian J Cancer ; 2011 Jan-Mar; 48(1): 24-30
Article in English | IMSEAR | ID: sea-144407

ABSTRACT

Background : 5-Flourouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival. Patients and Methods: A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively. Results : Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment begining, age below 60 years and early stage disease significantly improve OS and DFS in multivarite analysis. Conclusions: Survival is worse in patients older than 60 years, had late treatment begining, advanced stage and D0 dissection.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Adenocarcinoma/therapy , Adenocarcinoma, Mucinous/drug therapy , Adenocarcinoma, Mucinous/radiotherapy , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Antimetabolites, Antineoplastic/therapeutic use , Carcinoma, Papillary/drug therapy , Carcinoma, Papillary/radiotherapy , Carcinoma, Papillary/therapy , Carcinoma, Signet Ring Cell/drug therapy , Carcinoma, Signet Ring Cell/radiotherapy , Carcinoma, Signet Ring Cell/therapy , Combined Modality Therapy , Female , Fluorouracil/therapeutic use , Follow-Up Studies , Gastrectomy , Humans , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/drug therapy , Stomach Neoplasms/radiotherapy , Stomach Neoplasms/therapy , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL